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ABSTRACT 
Objective 
To review the indication and side effects of androgen deprivation therapy (ADT) in men 
affected by prostate cancer.  
Data Sources 
National guidelines, evidence-based summaries, peer-reviewed studies, and websites. 
Conclusion 
Indications for ADT include men with (1) intermediate to high-risk localised prostate cancer 
undergoing radiation therapy, (2) biochemical recurrence after radical prostatectomy treated 
with salvage radiation therapy or (3) metastatic prostate cancer. Several forms of ADT are 
available. To support self-management body weight, diet, physical activity, alcohol 
consumption and smoking should be discussed during clinical consultations. Important side-
effects of ADT may include flare-up phenomena of GnRH analogues, local reactions at 
 
 
injection sites, cardiovascular events, bone-loss/fractures, drug-drug interactions, urinary tract 
dysfunction, hot flashes, cognitive impairment, seizure falls and liver impairment. 
Implications for Nursing Practice 
Nurses have a role in personalized cancer care and they should be familiar with indications, 
side effects and interventions to optimize quality of life for men affected by prostate cancer 
receiving ADT. 
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INDICATIONS FOR ANDROGEN DEPRIVATION THERAPY 
Prostate cancer (PCa) represents one of the most common neoplasms among men with almost 
1’300’000 new cases and 360’000 deaths in 20181 accounting for 15% of all cancers diagnosed. 
Prostate cancer is the fifth leading cause of cancer death in men and represents 7% of total 
cancer mortality in men2. The disease is driven by androgen steroid hormones, which activate 
the androgen receptor (AR) transcription factor3. Given this dependency on testosterone in 
order to grow, the function of the AR receptor represents the main therapeutic target approached 
by several different strategies and summarized by the umbrella term androgen deprivation 
therapy (ADT). Currently available forms of ADT include bilateral orchiectomy, 
Gonadotropin-releasing hormone (GnRH) analogues or antagonists and anti-androgens. The 
indications for ADT mainly include men with (1) intermediate to high-risk localised prostate 
cancer undergoing radiation therapy, (2) biochemical recurrence after radical prostatectomy 
treated with salvage radiation therapy or (3) metastatic prostate cancer. 
 
Although there are many ways to target the AR, several clinical studies shed light which ADT 
should be initiated in which group of patients. Generally speaking there is no clear evidence in 
favor of orchiectomy, GnRH analogue or antagonist. However, in the specific case of patients 
 
 
with impending spinal cord compression guidelines recommend either orchidectomy or GnRH 
antagonists over GnRH analogues because GnRH antagonists don’t have the flare-up 
phenomena. In contrast, anti-androgens alone are only recommended in men with biochemical 
recurrence treated with salvage radiation therapy.  
Because disease specific recommendations do not exist, logistic and economic considerations 
may help to choose a certain ADT. For patients without access to medical care on a regular 
base, orchiectomy may represent an ideal option. Whereas men refraining from a mutilating 
surgery with negative psychological consequences may be offered GnRH analogue or 
antagonist. As indicated in Table 1, GnRH analogue implants have the advantage of easier 
application and are the preferred option from a caregiver4 and economic5 perspective, 
particularly if administered at 6 monthly applications 6. 
 
Despite ADT agents leading to response in nearly all metastatic prostate cancer patients, almost 
all patients will progress to castration resistant prostate cancer (CRPC), meaning that their 
cancer is growing despite castrate levels of testosterone. Advances in our understanding of the 
biology and progression mechanisms to CRPC has informed the development of next 
generation ADT drugs. Next generation ADT include abiraterone acetate (Zytiga®), 
enzalutamide (Xtandi®), apalutamide (Erleada®) and darolutamide (Nubeqa®) but can cost 
>50,000 $ per patients per year and some specific caveats must be kept in mind. Given the high 
prevalence of men requiring ADT together with an increasing complexity of the disease, nurses 
can optimize supportive care for men receiving ADT 7 and have the responsibility of 
administration and monitoring response to therapy and side-effect, while being safely 




SIDE EFFECTS OF ANDROGEN DEPRIVATION THERAPY 
Many men on ADT will grapple with side effects which can negatively affect physical and 
psychological outcomes, of both the man and his partner/spouse.  Therefore, providing patient 
education and awareness to optimize supported self-management strategies may improve 
quality of life and the couples adjustment. Several side effects of ADT can at least partially be 
prevented or ameliorated by following a healthy diet 8, maintaining a normal weight, engaging 
in physical activity 9-11 12, limiting alcohol consumption and smoking cessation. At each clinical 
consultation life-style modifications should be discussed, supported and encouraged by the 
healthcare professional to provide tailored self-management advice to meet the individual 
patients needs and preferences. In particular dietary instruction is also of importance regarding 
the timing of drug administration for example, abiraterone should be taken during fasting 




A unique consequence of GnRH analogues is the testosterone “flare-up” phenomenon which 
can be experienced for several days after the first injections and may lead to increased bone 
pain, acute bladder outlet obstruction, obstructive renal failure, spinal cord compression, and 
cardiovascular death13. Therefore, to protect patients from experiencing the testosterone flare 
following the administration of GnRH, patients are also given a first-generation anti-androgen 
during the first 2-4 weeks after initiation of GnRH analogues13. 
 
Local complications of ADT injections 
As outlined in Table 1 different GnRH analogues or antagonists are available. Although post-
injection bruising has been reported more frequently with the implant compared with a 
reconstituted formulation, there were no observed differences in pain levels or the requirement 
 
 
for analgesia  in men receiving different administration of ADT agents  4. Nurses should take 
care and caution while injecting the implant into the anterior abdominal wall due to the 
proximity of underlying inferior epigastric vessels and its branches. In case of painful injections 
or hematoma nurses must monitor patients according to the local reaction observed. Patients 
with anticoagulation or cachexia should be given a reconstituted formulation instead of an 
implant. Moreover, the reconstituted formulation should be administered slowly and the needle 
should not retracted too fast because this may lead to a local reaction if the skin comes into 
contact with the ADT formulation. Some of those local administration site reactions may be 
misinterpreted as an abscess in clinical practice which may result in unnecessary surgical 
removal for the patient.  
 
Cardiovascular complications 
After initiation of ADT men are likely to experience body weight gain, reduced insulin 
sensitivity and dyslipidemia14 therefore significantly increasing their risk for cardiovascular 
complications 15.   We recommend a cardiology consultation for men with a history of 
cardiovascular disease, and for men older than 65 years prior to starting ADT 13. Furthermore, 
life-style modifications, close monitoring of blood pressure, lipid profile, and blood glucose 
levels is recommended 15,16. 
Bone loss and fractures 
It has been observed that men receiving ADT show an increased bone turnover and decreased 
bone mineral density therefore increasing the risk of fractures. To reduce the risk of fractures 
life-style modifications, monitoring serum levels of vitamin D and calcium and early 
supplementation is recommended13. A personalized fracture risk assessment using the WHO 
FRAX tool (http://www.shef.ac.uk/FRAX) can be used in practice to decide whether a bone 
protective agent such as bisphosphonates or denosumab should be prescribed. Denosumab use 
is associated with an increased risk of osteonecrosis of the jaw and therefore, consultation with 
 
 
a dentist before starting of denosumab is strongly recommended. After initiation of ADT 
regular screening for risk factors to prevent fractures is advised using dual energy radiographic 
absorptiometry (DEXA) 16. 
 
Drug-drug interactions 
Men affected by prostate cancer represents an aging population with high co-medication use 
for multiple comorbidities and increased risk of drug-drug interactions. Next-generation ADT 
agents differ regarding their drug-drug-interactions and these can be observed in up to 85% of 
men, which include medications such as opiates, proton-pump inhibitors, statins, alpha-
blockers, anti-cholinergics and nifedipine 17,18. Because such drug-drug interactions can have 
fatal complications we strongly advise to always assess co-medication and perform a new drug 
interaction test before choosing next-generation ADT agents. 
 Urinary tract function 
Although ADT does decrease International Prostate Symptom Score (IPSS)patient self-
reported scores, prostate volume 19 and increases urinary flow20, men on ADT compared to 
healthy controls have a higher risk of experiencing lower urinary symptoms (LUTS) 21,22.  
Around 15% of men may require urethral dilatation and/or transurethral resection of the 
prostate (TURP) within 5 years of receiving ADT 23 24 . To improve LUTS, alpha blockers 25 
as well as choosing GnRH antagonists instead of GnRH analogues have been suggested in a 
recent study 26. Additionally, it should be kept in mind that the drug-drug-interaction of 
enzalutamide might minimize the efficacy of alpha-blockers and anti-cholinergics and 
therefore alternative options of next-generation ADT drugs should be considered. Progression 
of symptoms and the need for TURP is a worse predictor of cancer progression 27 but TURP 
can safely be offered and successfully improves local symptoms in 80% 28.   Additionally, 
bilateral orchiectomy can be performed under the same anesthesia.  Men on ADT have an 
increased risk of 20-30% 29 14 of developing acute kidney injury within the first year on ADT 
 
 
which is 2.5 higher odds compared to the matched controls 30. Urinary tract complications are 
frequent in men receiving ADT and therefore the benefit of regular assessment which should 
include urine flow, post void residual volume, renal sonography and creatinine assessment 
should be considered. 
 
Loss of energy and strength 
Loss of energy is often referred to as asthenia or fatigue and a common side effect in men 
undergoing ADT. Beside above-mentioned life-style modifications, screening for underlying 
diseases including anemia and hypothyroidism may offer therapeutic options to improve this 
debilitating side-effect in men Similarly muscle loss is a common symptom 31  and therefore, 
referring patients to an exercise physiologist and dietitian can be helpful to improve energy 
levels, strength, physical conditioning, and mood in men receiving ADT. 
 
Hot flushes 
Hot flushes affect up to 75% of men treated with ADT but there are limited therapeutic options 
to alleviate this side-effect.  There are several agents such as clonidine 32 and gabapentin 33 
which has demonstrated a  limited efficacy in controlling hot flushes.  Whereas, other agents 
which include estrogen 34 or progestational 35 have displayed a significant reduction in hot 
flushes but were associated with further side-effects. Despite limited evidence on the efficacy 
of such agents in controlling hot flushes, current clinical guidelines recommend prescribing a 
selective serotonin or noradrenergic reuptake inhibitors16. More recently, anti-cholinergics have 
been discussed as potential treatment options for hot flushes in prostate cancer patients 36 as a 
clear efficacy has been shown in postmenopausal women 37 and breast cancer survivors who 
were receiving tamoxifen or aromatase inhibitors 38.  However, further research is needed to 




Sexual function and genital changes 
A decrease in libido and erectile dysfunction is experienced in most patients on ADT, which 
can result in changes in the couple’s relationship.  A multidisciplinary ADT Survivorship 
Working Group suggested to prepare the couple for changes in sexual function and discuss 
couple centered goals and expectation before administering ADT.  Sexual well-being 
interventions can be offered and discussed such as,  phosphodiesterase 5 inhibitors, vacuum 
therapy to promote quality erections, transdermal estradiol for desire, and sexual 
therapy/mindfulness techniques39.  Noteworthy, the influence of estradiol on oncological and 
cardiovascular outcomes is unclear and should only be recommended with caution. 
 
To ensure individualized couple preferences and needs are met, intervene early and discuss 
realistic expectation by promoting flexibility and talk in an open and nonjudgmental manner.  
Moreover, healthcare professionals should encourage intimacy despite low libido such as 
physical affection such as holding hands, hugging, physical touch, kissing, and cuddling to 
prevention erosion in spousal bond. 
Increase in breast size or tenderness occurs in 90% of men with anti-androgens and 30% on 
GnRH analogue or antagonist and genital shrinkage including penile length and testicular size 
occurs in >90% 40. Either radiotherapy of the breasts41 or daily tamoxifen (20mg) could prevent 
gynecomastia41,42 and mastectomy or liposuction could be used to manage existing breast 
enlargement 39.  Provide psychological support as men can experience feelings of 
embarrassment related to gynecomastia, review analgesia for pain/discomfort, and suggest the 






Several retrospective studies suggested an association between ADT with cognitive 
impairment43, Alzheimer's disease44, depression 45, suicide and falls46. As shown in localised 
prostate cancer patients group-based cognitive-behavioral stress management could improve 
quality of life 47 48 whereas there are no definite recommendations to prevent or treat cognitive 
impairment. The additional negative impact of next-generation ADT needs to be clarified, 
specifically as they differ substantially regarding blood brain barrier penetration49.   
Liver function 
Prostate cancer patients on ADT compared to men not on ADT may have an increased risk for 
liver diseases 50. ecause hepatic impairment decreases the elimination of abiraterone, men 
treated with abiraterone are at risk for liver dysfunction and abiraterone is contraindicated in 
men with severe hepatic impairment 18,51. 
Nursing Implications 
Beside the manys side-effects discussed above, it has to be expected that many other medical 
or social issues may arise during ADT for the man and his partner/spouse.  
 
 
Each consultation with a patient and his partner/spouse is exceptionally unique and provides the healthcare professional with a very privileged glimpse into a person’s life and concerns at that moment. A nurse consultation provides an opportunity to explore the patient’s problems and identify areas of most concern to tailor intervention at the individual level of need which will invariably change over the cancer care continuum.  Therefore, we would recommend regular screening by structured interviews, or patient reported outcome measures such as Holistic Needs Assessments (HNA) to identify areas of concern.  Implementing paper and pen HNA in routine clinical practice means that men do not have to verbalise embarrassing concerns aloud, but instead the nurse can tactfully focus the consultation to the areas of most concern to the man and partner/spouse as identified in the HNA to ensure personalised and optimal care.CONCLUSION 
Nurses are a valuable contact for patients and their families and provide care co-ordination 
across the multidisciplinary team for men affected by prostate care receiving ADT.  Nurses 
must be educated in the indications and side-effects of androgen deprivation therapy.  
Moreover, nurse should provide evidence-based interventions to alleviate side-effects, signpost 
patients for supportive care services in the community, and refer patients as appropriate to the 
MDT team.  Given the complexity of prostate cancer therapies arising from ADT side effects 
nurses are the hub of cancer care to educate patients and families about expected side-effects 
of ADT, offered supported self-management to ultimately improve quality of life, costs and 
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Drug Goserelin acetate Leuprorelin acetate Leuprorelin acetate Leuprorelin acetate Triptorelin acetate Buserelin acetate Degarelix acetate Abarelix 
Brand name1 Zoladex® 
Leuprorelin 
Sandoz® 
Lupron Depot® Eligard® Decapeptyl® SR Suprefact® Firmagon® Plenaxis® 
Mode of action LHRH-Agonist LHRH-Agonist LHRH-Agonist LHRH-Agonist LHRH-Agonist LHRH-Agonist LHRH-Antagonist LHRH-Antagonist 
Preparation Implant Implant Microspheres Powder2 Powder 2,3 Implant Powder 2 Powder 2 













Dose Always same dose Always same dose Always same dose Always same dose Always same dose Always same dose 
First dose 2x120mg 
Regular dose 80mg 
Always same dose 
Dosing frequency 1-, or 3-monthly 1-, or 3-monthly 1-, 3-, 4- or 6-monthly 1-, 3-, 4- or 6-monthly 1-, 3-, or 6-monthly 2-, 3-, monthly 1-monthly 2-weekly 
Storage conditions <25°c <30°C <30°C 2-8°C <25°c <25°c <25°c <25°c 
 
 
Needle diameter 14-16G 14G 21-23G 18-20G 19-21G  25G 18G 
 
Table 1 Overview of advantages and disadvantages of available LHRH Agonists and Antagonists,  
1varies by country, 2 needs Up to 15 minutes to dissolve, 3 needs time to reach room temperature 
Abbreviations LHRH: luteinizing hormone-releasing hormone, s.c.: subcutaneous, i.m.: intramuscular, °C: Degree Celsius, G: gauge 
